GGT3 Antibody

Detection in Cell and Tissue Samples

The EPR28715-82 antibody demonstrates robust reactivity in diverse biological samples:

Functional Studies

• Immunoprecipitation (IP): Successfully pulled down GGT1/GGT3 from HepG2 lysates, confirmed by VeriBlot IP detection .

• Immunohistochemistry (IHC): Localized GGT1/GGT3 to capillary endothelial cells in the nervous system and renal proximal tubules .

• Immunofluorescence: Visualized GGT1/GGT3 in HepG2 cells with Alexa Fluor® 488 conjugation, highlighting membrane-bound localization .

3. Comparative Analysis of GGT Isoforms
The EPR28715-82 antibody enables differentiation between GGT isoforms in transfected 293T cells:

This specificity is critical for studying isoform-specific roles in metabolism and disease .

Clinical and Diagnostic Relevance

• Tumor Markers: GGT overexpression is linked to cancer progression, with antibodies like GGT129 (a separate anti-GGT antibody) aiding in tumor detection .

• Autoimmune Diseases: While not directly studied for GGT3, anti-glycan antibodies (e.g., GT3 ganglioside) are implicated in autoimmune conditions like Guillain-Barré syndrome, highlighting broader antibody therapeutics research .

Technical Considerations

• Optimal Conditions:

  • Western Blot: 1/1000 dilution, 5% NFDM/TBST blocking buffer .

  • IHC: 1/100 dilution, heat-mediated antigen retrieval (Tris-EDTA buffer, pH 9.0) .

• Limitations:

  • Variable band sizes (e.g., 36 kDa in some samples) may reflect post-translational modifications or proteolytic cleavage .

  • Low expression in skeletal muscle and HEK-293 cells necessitates optimized protocols .

References

1. Elevated anti-GT3 ganglioside antibodies in type I diabetes .

2. Anti-glycan antibodies in autoimmune diseases .

3. EPR28715-82 antibody validation in cell lysates and tissues .

4. GGT129 antibody for GGT localization in human tissues .